Daniella Livnat

Learn More
A collaborative study was organized to identify monoclonal antibodies (MAbs) that may be broadly and potently neutralizing for a panel of human immunodeficiency virus type 1 (HIV-1) low-passaged adult and pediatric primary isolates in peripheral blood mononuclear cells. Five laboratories evaluated a coded panel of seven human MAbs to HIV-1 subtype B(More)
Regulation of the growth of murine B-cell lymphomas has been used as a model for tolerance induction. The inhibition by anti-immunoglobulin reagents of the growth of WEHI-231 and several variant clones has now been studied. The parental line is exquisitely sensitive to growth inhibition by heterologous or monoclonal anti-mu or anti-k reagents and ceases to(More)
B cell lymphomas which can be growth inhibited by crosslinking their surface IgM receptors by anti-Ig reagents provide models for normal B cell regulation and tolerance. WEHI-231 and CH31 are two independently derived lines that are exquisitely sensitive to negative signalling by antibodies specific for mu or kappa chains, but are unaffected by antibodies(More)
WEHI-231 B lymphoma cells have proven to be a useful model for the regulation of growth of normal B cells by anti-Ig reagents. We previously reported that the growth of these lymphoma cells is inhibited by heterologous or monoclonal anti-mu or anti-kappa reagents. Such cells cease to incorporate thymidine within 24-48 h of exposure to anti-Ig reagents, but(More)
It has become increasingly apparent that B lymphomas provide clonal models for antigen-specific lymphocytes and for the analysis of both positive and negative signalling in B cells. In addition, anti-Ig reagents have been used to mimic antigen/tolerogen in their interaction with B cell receptors at a polyclonal level (1-3). We have been studying the effects(More)
Spleen and bone marrow cells from DBA/2 mice protected against infection with a leukemogenic dose of Friend leukemia virus (FLV) by passive therapy with chimpanzee anti-FLV serum were shown to be able to adoptively transfer antiviral resistance to unimmunized irradiated syngeneic recipients. Similar to the results obtained with donor mice immunized against(More)
Previous studies have demonstrated that the passive therapy of Friend murine leukemia virus (F-MuLV)-induced disease with chimpanzee anti-F-MuLV serum is accompanied by the development of host antiviral humoral and cellular immunity, the latter measurable in adoptive transfer protocols and by the ability of serum-protected mice to resist virus rechallenge.(More)